Effect of etelcalcetide on parathyroid hormone secretion by primary hyperparathyroidism patient-derived primary parathyroid cells
Autor: | Hiroyuki Yamada, Masaaki Inaba, Yoshihiro Sugiura, Kazutsune Harada, Atsuto Inoue, Masanori Emoto, Tomoe Hirakawa, Mikiyasu Taguchi, Ikue Kobayashi, Noriyuki Hayashi, Yasuo Imanishi, Daichi Miyaoka, Aiko Fujioka |
---|---|
Rok vydání: | 2020 |
Předmět: |
Male
0301 basic medicine medicine.medical_specialty Calcimimetic Endocrinology Diabetes and Metabolism Parathyroid hormone 030209 endocrinology & metabolism Parathyroid Glands 03 medical and health sciences 0302 clinical medicine Endocrinology Internal medicine Animals Humans Medicine Orthopedics and Sports Medicine Cells Cultured Etelcalcetide business.industry General Medicine Parathyroid chief cell Middle Aged Hyperparathyroidism Primary medicine.disease Rats Parathyroid Hormone Parathyroid hormone secretion Female Secondary hyperparathyroidism 030101 anatomy & morphology Calcium-sensing receptor Peptides business hormones hormone substitutes and hormone antagonists Primary hyperparathyroidism |
Zdroj: | Journal of Bone and Mineral Metabolism. 39:396-403 |
ISSN: | 1435-5604 0914-8779 |
DOI: | 10.1007/s00774-020-01158-2 |
Popis: | Etelcalcetide (Parsabiv®, AMG 416/ONO-5163) is a novel allosteric modulator for the calcium-sensing receptor approved for hemodialysis patients with secondary hyperparathyroidism of uremia. Etelcalcetide reduced parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism of uremia in clinical studies. However, its direct effect on parathyroid hormone secretion in human parathyroid cells remains unknown. This study aimed to determine if etelcalcetide suppresses parathyroid hormone secretion by human parathyroid cells in vitro. We prepared primary cell cultures from human parathyroid tissue and determined calcium-sensing receptor expression levels by immunohistochemistry. Pathyroid tumors were removed from fourteen patients with primary hyperparathyrodism. Parathyroid tissue was dispersed with collagenase, resuspended in culture medium, incubated for 2 h with etelcalcetide and Ca2+, and the medium was then collected. Final etelcalcetide concentrations in the medium were 0.005–50 µmol/L. Levels of human parathyroid hormone in the medium were determined by enzyme-linked immunosorbent assay. In eight of the fourteen parathyroid cell cultures, extracellular Ca2+ reduced parathyroid hormone levels. In four of the eight parathyroid cell cultures which responded extracellular Ca2+, etelcalcetide reduced hormone secretion with the 50% effective concentrations of 0.57, 20.8, 0.42, and 0.57 µmol/L. Expression levels of the calcium-sensing receptor were significantly lower in primary hyperparathyroidism patient-derived parathyroid tissues compared with controls. This is the first report that etelcalcetide directly reduced parathyroid hormone secretion from the primary cultured human parathyroid cells from patients with primary hyperparathyroidism. To verify this conclusion, further studies are needed using secondary hyperparathyroidism patient-derived parathyroid cells. |
Databáze: | OpenAIRE |
Externí odkaz: |